Detalles de la búsqueda
1.
Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland.
Clin Invest Med
; 44(1): E38-41, 2021 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33743575
2.
Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?
Future Oncol
; 18(6): 635-638, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35018801
3.
Advancing the systemic therapy of lung cancer: quality or quantity?
Lancet Oncol
; 21(3): 322-324, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035512
4.
The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts.
BMC Cancer
; 15: 112, 2015 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25884767
5.
A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic.
Cancer Treat Res Commun
; 34: 100678, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36608489
6.
An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic.
Immunotherapy
; 15(12): 921-932, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37431608
7.
Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.
Cancer Treat Res Commun
; 36: 100747, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37531737
8.
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
JTO Clin Res Rep
; 4(10): 100562, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37744308
9.
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Nat Med
; 29(10): 2559-2569, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37814061
10.
Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors.
Immunotherapy
; 14(10): 777-787, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35678046
11.
Outcomes of Hypofractionated Stereotactic Radiotherapy for Small and Moderate-Sized Brain Metastases: A Single-Institution Analysis.
Front Oncol
; 12: 869572, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35444935
12.
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC.
Lung Cancer
; 171: 42-46, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35907387
13.
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Curr Oncol
; 29(7): 4428-4437, 2022 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35877212
14.
A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Cancer Treat Res Commun
; 27: 100330, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581492
15.
A real-world comparison of cisplatin vs cetuximab used concurrently with radiation in the treatment of locally advanced oropharyngeal carcinoma.
Head Neck
; 43(1): 153-163, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32949087
16.
A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada.
JTO Clin Res Rep
; 2(12): 100249, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34877555
17.
CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients.
PLoS One
; 16(1): e0241240, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33507926
18.
Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients.
Transl Lung Cancer Res
; 10(2): 826-838, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33718025
19.
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Cancer Med
; 9(13): 4640-4647, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32378799
20.
Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report.
Clin Lung Cancer
; 23(8): e563-e567, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36153193